Research progress of clinical application of copeptin in different diseases

doi:10.3969/j.issn.1673-8640.2022.03.020

Abstract

Abstract:

Copeptin is the C-terminal peptide of the precursor molecule of arginine vasopressin（AVP）,which can be released into the blood equimolar with AVP by equal molar,and the half-life of it is about 14 d,which is stable and easy to detect. Copeptin has low specificity and no organ specificity,but it has high positive predictive value and high sensitivity for acute myocardial infarction（AMI）,stroke,chronic kidney disease and other diseases. This review focuses on the clinical application of copeptin in cardiovascular disease,liver disease,kidney disease,respiratory disease and stroke.

Key words: Copeptin, Cardiovascular and cerebrovascular diseases, Liver disease, Kidney disease, Respiratory disease

CLC Number:

R446.1

MAO Jie, LU Qingqing, LI Ping, SHI Shengjie, LI Jing, DENG Changjuan, TAN Chaochao, XIE Xiaobing. Research progress of clinical application of copeptin in different diseases[J]. Laboratory Medicine, 2022, 37(3): 291-294.

References 25

[1]	TASNEEM M, MANNIX C, WONG A, et al. Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?[J]. World J Nephrol, 2018, 7(2):51-57. DOI URL
[2]	HARPER K M, KNAPP D J, CRISWELL H E, et al. Vasopressin and alcohol:a multifaceted relationship[J]. Psychopharmacology(Berl), 2018, 235(12):3363-3379. DOI URL
[3]	PAMUKCU H E, FELEKOLU M A, ALGÜL E, et al. Copeptin levels predict left ventricular systolic function in STEMI patients:a 2D speckle tracking echocardiography-based prospective observational study[J]. Medicine(Baltimore), 2020, 99(50):e23514.
[4]	韦有全, 黄海清. 血管加压素的心血管效应与临床应用研究进展[J]. 中国医学创新, 2018, 15(2):139-144.
[5]	王琦, 校建波, 李海荣, 等. 急性心肌梗死并发心源性休克与血管紧张素、儿茶酚胺、血管加压素的关系分析[J]. 疑难病杂志, 2018, 17(10):1081-1084.
[6]	方晓君. 血管加压素使用时机和脓毒性休克的死亡率:队列研究[J]. 创伤与急诊电子杂志, 2016, 4(2):123.
[7]	李津健. 血浆和肽素及cTn Ⅰ检测在急性冠状动脉综合征诊断中的应用价值分析[J]. 医学理论与实践, 2019, 32(5):732-733.
[8]	PEDERSEN C K, STENGAARD C, SØNDERGAARD H, et al. A multicentre,randomized,controlled open-label trial to compare an accelerated rule-out protocol using combined prehospital copeptin and in-hospital high sensitive troponin with standard rule-out in patients suspected of acute myocardial infarction-the AROMI trial[J]. Trials, 2018, 19(1):683. DOI URL
[9]	SHIN H, JANG B H, LIM T H, et al. Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction:a systematic review and meta-analysis[J]. PLoS One, 2018, 13(7):e0200379. DOI URL
[10]	JEONG J H, SEO Y H, AHN J Y, et al. Performance of copeptin for early diagnosis of acute myocardial infarction in an emergency department setting[J]. Ann Lab Med, 2020, 40(1):7-14. DOI URL
[11]	MORAWIEC B, PRZYWARA-CHOWANIEC B, MUZYK P, et al. Combined use of high-sensitive cardiac troponin,copeptin,and the modified HEART score for rapid evaluation of chest pain patients[J]. Dis Markers, 2018, 2018:9136971.
[12]	KERBERT A J C, VERSPAGET H W, NAVARRO À A, et al. Copeptin in acute decompensation of liver cirrhosis:relationship with acute-on-chronic liver failure and short-term survival[J]. Crit Care, 2017, 21(1):321. DOI URL
[13]	BARCHETTA I, ENHÖRNING S, CIMINI F A, et al. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity[J]. BMC Med, 2019, 17(1):85. DOI URL
[14]	POPOVIC M, EBRAHIMI F, URWYLER S A, et al. The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome[J]. Endocr Connect, 2020, 9(7):715-723. DOI URL
[15]	KIM J S, YANG J W, CHAI M H, et al. Copeptin in hemodialysis patients with left ventricular dysfunction[J]. Yonsei Med J, 2015, 56(4):976-980. DOI URL
[16]	AFSAR B. Pathophysiology of copeptin in kidney disease and hypertension[J]. Clin Hypertens, 2017, 23:13. DOI URL
[17]	EL BOUSTANY R, TASEVSKA I, MEIJER E, et al. Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population[J]. JCI Insight, 2018, 3(13):e121479. DOI URL
[18]	GANSEVOORT R T, VAN GASTEL M D A, CHAPMAN A B, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease[J]. Kidney Int, 2019, 96(1):159-169. DOI URL
[19]	SCHOEN T, HOHMANN E M, VAN DER LELY S, et al. Plasma copeptin levels and ambulatory blood pressure characteristics in healthy adults[J]. J Hypertens, 2015, 33(8):1571-1579. DOI URL
[20]	BHANDARI S S, LOKE I, DAVIES J E, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals[J]. Clin Sci(Lond), 2009, 116(3):257-263. DOI URL
[21]	ABBASI A, CORPELEIJN E, MEIJER E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes:the Prevention of Renal and Vascular Endstage Disease(PREVEND) study[J]. Diabetologia, 2012, 55(7):1963-1970. DOI URL
[22]	CHOI K S, KIM H J, CHUN H J, et al. Prognostic role of copeptin after stroke:a systematic review and meta-analysis of observational studies[J]. Sci Rep, 2015, 5:11665. DOI URL
[23]	陈加平, 徐令奇, 谭彩萍, 等. 血浆和肽素水平与急性脑梗死患者病情及近期预后的关系分析[J]. 临床和实验医学杂志, 2019, 18(5):489-492.
[24]	许安春, 熊大迁, 江梦曦, 等. 和肽素、PCT、CRP和NLR检测对慢性阻塞性肺疾病伴呼吸衰竭患者的诊断价值[J]. 检验医学与临床, 2020, 17(22):3298-3300.
[25]	胡诗礼, 李丽华, 张李, 等. 血清IL-17和CHE及和肽素水平与老年 COPD合并肺部感染的相关性[J]. 中华医院感染学杂志, 2020, 30(21):3272-3276.